VBI Vaccines Announces Development of a Novel Glioblastoma Immunotherapy Candidate

By: via Benzinga
VBI Vaccines Inc. (Nasdaq: VBIV) ("VBI") today announced that it has applied its eVLP Platform in the development of a novel therapeutic ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.